Document Detail

Practice parameter: recurrent stroke with patent foramen ovale and atrial septal aneurysm: report of the Quality Standards Subcommittee of the American Academy of Neurology.
MedLine Citation:
PMID:  15078999     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: 1) To evaluate the risk of subsequent stroke or death in patients with a cryptogenic stroke and a patent foramen ovale (PFO), atrial septal aneurysm (ASA), or both. 2) To establish the optimal method of stroke prevention in this population of patients. METHODS: MEDLINE, the Cochrane database of systematic reviews, key meeting abstracts from 1997 to 2002, and relevant reference lists were searched to select studies that prospectively collected outcome data in cryptogenic stroke patients with and without interatrial septal abnormalities. Studies were also selected that prospectively compared at least two treatment options. The quality of each study was graded (class I to IV) using a standard classification-of-evidence scheme for each question. Risk analyses were performed and data were pooled when appropriate. RESULTS: The literature search generated 129 articles of which only four fulfilled the inclusion and exclusion criteria. Two studies were graded class I, one study was graded class II, and one study was graded class IV for prognosis. Pooled results of the two class I and one class II studies demonstrated no increased risk of subsequent stroke or death in patients with PFO compared to those without (RR = 0.95, 95% CI 0.62 to 1.44). One class I study found increased risk of recurrent stroke in patients with PFO and ASA (annual rate = 3.8% versus 1.05%, RR = 2.98, 95% CI 1.17 to 7.58) but not increased risk of a composite of stroke and death (annual rate = 3.8% versus 1.8%, RR = 2.10, 95% CI 0.86 to 5.06). Regarding therapy, one study was graded class II, one study class III, and two studies class IV. Among patients with cryptogenic stroke and PFO or ASA, there was no significant difference in stroke or death rate in warfarin-treated patients relative to aspirin-treated patients and the confidence intervals were unable to rule out a benefit of one drug over the other (annual rate = 4.7% versus 8.9%, RR = 0.53, 95% CI 0.18 to 1.58). Minor bleeding rates were higher in the cohort of patients who received warfarin (22.9/100 patient-years versus 8.66/100 patient-years, rate ratio = 2.64, p < 0.001). No studies compared medical therapy with surgical or endovascular closure. CONCLUSION: PFO is not associated with increased risk of subsequent stroke or death among medically treated patients with cryptogenic stroke. However, both PFO and ASA possibly increase the risk of subsequent stroke (but not death) in medically treated patients younger than 55 years. In patients with a cryptogenic stroke and an atrial septal abnormality the evidence is insufficient to determine if warfarin or aspirin is superior in preventing recurrent stroke or death, but minor bleeding is more frequent with warfarin. There is insufficient evidence to evaluate the efficacy of surgical or endovascular closure.
S R Messé; I E Silverman; J R Kizer; S Homma; C Zahn; G Gronseth; S E Kasner;
Related Documents :
18794219 - Evidence of increased motoneuron excitability in stroke patients without clinical spast...
10818539 - Relevance of white matter changes to pre- and poststroke dementia.
16330869 - Combined carotid and transcranial ultrasound findings compared with clinical classifica...
25285269 - Serial pulmonary function tests to diagnose copd in chronic heart failure.
15061829 - Young stroke and basal plasma and post-methionine load homocysteine and cysteine levels...
15311349 - Hemichorea after stroke: clinical-radiological correlation.
16408539 - Complications of managing the airway.
21749449 - The jak2v617f allele burden and stat3- and stat5 phosphorylation in myeloproliferative ...
7611099 - Screening for abdominal aortic aneurysms during transthoracic echocardiography.
Publication Detail:
Type:  Guideline; Journal Article; Practice Guideline; Review    
Journal Detail:
Title:  Neurology     Volume:  62     ISSN:  1526-632X     ISO Abbreviation:  Neurology     Publication Date:  2004 Apr 
Date Detail:
Created Date:  2004-04-13     Completed Date:  2004-08-02     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0401060     Medline TA:  Neurology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1042-50     Citation Subset:  AIM; IM    
Department of Neurology, University of Pennsylvania, Philadelphia, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cohort Studies
Heart Aneurysm / diagnosis,  epidemiology*,  therapy
Heart Atria / pathology*
Heart Septal Defects, Atrial / diagnosis,  epidemiology*,  therapy
Middle Aged
Prospective Studies
Recurrence / prevention & control
Risk Assessment
Stroke / epidemiology*,  prevention & control*
Comment In:
Neurology. 2004 Dec 14;63(11):2198-9; author reply 2198-9   [PMID:  15602809 ]
Neurology. 2004 Dec 14;63(11):2198-9; author reply 2198-9   [PMID:  15596792 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  G2 checkpoint abrogators as anticancer drugs.
Next Document:  Aromatic L-amino acid decarboxylase deficiency: clinical features, treatment, and prognosis.